Searching News Database: ABSSSI
HSMN NewsFeed - 16 Mar 2020
ADVANZ PHARMA Corp. Limited to Acquire Specialty Pharmaceutical Company Correvio Pharma Corp.
ADVANZ PHARMA Corp. Limited to Acquire Specialty Pharmaceutical Company Correvio Pharma Corp.
HSMN NewsFeed - 24 Dec 2019
Correvio Receives Complete Response Letter From U.S. FDA for Brinavess and Provides Update on Recent Events
Correvio Receives Complete Response Letter From U.S. FDA for Brinavess and Provides Update on Recent Events
HSMN NewsFeed - 11 Dec 2019
Correvio Announces Intention to Explore Strategic Alternatives to Maximize Stakeholder Value
Correvio Announces Intention to Explore Strategic Alternatives to Maximize Stakeholder Value
HSMN NewsFeed - 25 Jul 2019
U.S. FDA Accepts Correvio's Resubmitted New Drug Application For Brinavess (vernakalant)
U.S. FDA Accepts Correvio's Resubmitted New Drug Application For Brinavess (vernakalant)
HSMN NewsFeed - 2 Jan 2019
Correvio Announces Chief Executive Officer Succession Plan and Other Board and Executive Changes
Correvio Announces Chief Executive Officer Succession Plan and Other Board and Executive Changes
HSMN NewsFeed - 17 May 2018
Correvio Announces Enrollment of First Patient in Phase 3 Study Evaluating Brinavess(R) in China
Correvio Announces Enrollment of First Patient in Phase 3 Study Evaluating Brinavess(R) in China
HSMN NewsFeed - 17 Apr 2018
Cardiome Completes Enrollment in the Post Approval Safety Study SPECTRUM Evaluating Brinavess(R)
Cardiome Completes Enrollment in the Post Approval Safety Study SPECTRUM Evaluating Brinavess(R)
HSMN NewsFeed - 12 Dec 2017
Cardiome Announces Strategic Licensing Agreement To Commercialize Aggrastat In Russia
Cardiome Announces Strategic Licensing Agreement To Commercialize Aggrastat In Russia
HSMN NewsFeed - 12 Jun 2017
Cardiome Announces Commercial Launch of BRINAVESS(R) (Vernakalant Hydrochloride) in Canada
Cardiome Announces Commercial Launch of BRINAVESS(R) (Vernakalant Hydrochloride) in Canada
HSMN NewsFeed - 3 Mar 2017
Cardiome Announces Commercial Launch of Xydalba(TM) (dalbavancin) in France
Cardiome Announces Commercial Launch of Xydalba(TM) (dalbavancin) in France
HSMN NewsFeed - 8 Dec 2016
Cardiome Announces Commercial Launch of Xydalba(TM) (dalbavancin) in the UK
Cardiome Announces Commercial Launch of Xydalba(TM) (dalbavancin) in the UK
HSMN NewsFeed - 26 Sep 2016
MicuRx Closes $55 Million Series C Financing to Support Development of Next-Generation Antibiotic MRX-I
MicuRx Closes $55 Million Series C Financing to Support Development of Next-Generation Antibiotic MRX-I
HSMN NewsFeed - 7 Sep 2016
FDA Grants Special Designation to TAXIS Pharmaceuticals Experimental Antibiotic
FDA Grants Special Designation to TAXIS Pharmaceuticals Experimental Antibiotic
HSMN NewsFeed - 31 May 2016
Allergan Receives FDA Approval of TEFLARO(R) (ceftaroline fosamil) for Pediatric Patients
Allergan Receives FDA Approval of TEFLARO(R) (ceftaroline fosamil) for Pediatric Patients
HSMN NewsFeed - 12 May 2016
Cardiome Announces the Launch of ESMOCARD Solution for Injection in France
Cardiome Announces the Launch of ESMOCARD Solution for Injection in France
HSMN NewsFeed - 16 Feb 2016
FDA Accepts Supplemental New Drug Application (sNDA) for TEFLARO(R) (ceftaroline fosamil)
FDA Accepts Supplemental New Drug Application (sNDA) for TEFLARO(R) (ceftaroline fosamil)
HSMN NewsFeed - 23 Jan 2016
Cellceutix Releases Data Used in Receiving FDA Orphan Drug Designation of Kevetrin for Pancreatic Cancer
Cellceutix Releases Data Used in Receiving FDA Orphan Drug Designation of Kevetrin for Pancreatic Cancer
HSMN NewsFeed - 21 Jan 2016
Allergan Announces FDA Approval of Updated Label for New Dosing Regimen for DALVANCE(R) (dalbavancin)
Allergan Announces FDA Approval of Updated Label for New Dosing Regimen for DALVANCE(R) (dalbavancin)
HSMN NewsFeed - 1 Jul 2014
Paratek Appoints Michael Bigham as Chairman and CEO and Promotes Evan Loh to President and CMO
Paratek Appoints Michael Bigham as Chairman and CEO and Promotes Evan Loh to President and CMO
HSMN NewsFeed - 5 Jun 2014
ORBACTIV(TM) (Oritavancin) Phase 3 Trial Results Published in New England Journal of Medicine
ORBACTIV(TM) (Oritavancin) Phase 3 Trial Results Published in New England Journal of Medicine
HSMN NewsFeed - 30 Dec 2013
Cubist Announces FDA Acceptance of Tedizolid New Drug Application with Priority Review
Cubist Announces FDA Acceptance of Tedizolid New Drug Application with Priority Review
HSMN NewsFeed - 20 Dec 2013
Cellceutix Files Orphan Drug Designation Application for Brilacidin for Oral Mucositis with US FDA
Cellceutix Files Orphan Drug Designation Application for Brilacidin for Oral Mucositis with US FDA
HSMN NewsFeed - 26 Jul 2012
Durata Therapeutics Adds Independent Director Lisa M. Giles to the Company’s Board
Durata Therapeutics Adds Independent Director Lisa M. Giles to the Company’s Board
HSMN NewsFeed - 5 Jan 2011
Cempra Pharmaceuticals Names Carl Foster Executive Vice President of Business Development
Cempra Pharmaceuticals Names Carl Foster Executive Vice President of Business Development